Coherus Oncology, Inc.
28
10
12
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 40/100
10.7%
3 terminated/withdrawn out of 28 trials
75.0%
-11.6% vs industry average
18%
5 trials in Phase 3/4
67%
6 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (28)
Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer
Role: collaborator
Trial of Atezolizumab and Bevacizumab With CHS-388 or Placebo in Patients With Hepatocellular Carcinoma
Role: lead
PhII Study of Toripalimab Followed by Definitive CRT & Adjuvant Toripalimab in Locally Advanced ESCC
Role: collaborator
Toripalimab With Chemotherapy for Sinus Cancer
Role: collaborator
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
Role: collaborator
Study of CHS-114 in Participants With Advanced Solid Tumors
Role: lead
Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases
Role: collaborator
A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer
Role: lead
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Role: lead
A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
Role: lead
Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
Role: lead
PDT For Induction Therapy For Head And Neck Cancer
Role: collaborator
Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)
Role: collaborator
Window of Opportunity in Preserving Laryngeal Function Trial
Role: collaborator
A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients
Role: collaborator
Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC
Role: collaborator
Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer
Role: lead
Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors
Role: lead
A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors
Role: lead
Study of SRF617 in Patients With Advanced Solid Tumors
Role: lead